CORC

在结果中检索

CORC

浏览/检索结果: 共11条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment 期刊论文
CANCER BIOLOGY & MEDICINE, 2018, 卷号: 15, 期号: 4
作者:  Wang, Jing;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/04
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial 期刊论文
JAMA ONCOLOGY, 2018, 卷号: 4, 期号: 11
作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/04
Predictors of recurrence and survival of pathological T1N0M0 invasive adenocarcinoma following lobectomy 期刊论文
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 卷号: 144, 期号: 6
作者:  Wang, Yiyang;  Zheng, Difan;  Zheng, Jiajie;  Huang, Qingyuan;  Han, Baohui
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. 期刊论文
JAMA Oncology, 2018, 卷号: 4, 期号: 11, 页码: 1569-1575
作者:  Han, Baohui*;  Li, Kai*;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载：7/0  |  提交时间：2019/12/03
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) 期刊论文
British Journal of Cancer, 2018, 卷号: 118, 期号: 5, 页码: 654-661
作者:  Han, Baohui*;  Li, Kai;  Zhao, Yizhuo;  Li, Baolan;  Cheng, Ying
收藏  |  浏览/下载：9/0  |  提交时间：2019/12/03
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. 期刊论文
JAMA oncology, 2018, 卷号: 4, 页码: 1569-1575
作者:  Han Baohui;  Li Kai;  Wang Qiming;  Zhang Li;  Shi Jianhua
收藏  |  浏览/下载：5/0  |  提交时间：2019/11/26
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment 期刊论文
CANCER BIOLOGY & MEDICINE, 2018, 卷号: 15, 页码: 443-451
作者:  Wang, Jing;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载：5/0  |  提交时间：2019/11/26
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial 期刊论文
JAMA ONCOLOGY, 2018, 卷号: 4, 期号: 11, 页码: 1569-1575
作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载：1/0  |  提交时间：2019/12/11
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial 期刊论文
2018, 卷号: 4, 期号: 11, 页码: 1569-1575
作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) 期刊论文
2018, 卷号: 118, 期号: 5, 页码: 654-661
作者:  Han, Baohui;  Li, Kai;  Zhao, Yizhuo;  Li, Baolan;  Cheng, Ying
收藏  |  浏览/下载：9/0  |  提交时间：2020/01/03

©版权所有 ©2017 CSpace - Powered by CSpace